apraclonidine has been researched along with Intraocular Pressure in 140 studies
apraclonidine: relieves postoperative intraocular pressure following trabeculoplasty; RN given refers to parent cpd
apraclonidine : An imidazoline that is 2-amino 4,5-dihydro-1H-imidazoline in which one of the exocyclic amino hydrogens has been replaced by a 4-amino-2,6-dichlorophenyl group.
Intraocular Pressure: The pressure of the fluids in the eye.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5% apraclonidine on Intraocular pressure (IOP) in horses and compare the effects of timolol maleate 0." | 9.51 | Effect of Topically Applied 0.5% Apraclonidine Versus 0.5% Timolol Maleate on Intraocular Pressure of Healthy Horses. ( Asghari, A; Ozmaie, S; Rajaei, SM; Ziadi, A, 2022) |
| "PRéCIS:: Adjuvant diclofenac and apraclonidine eye drop given in conjunction with selective laser trabeculoplasty (SLT) do not significantly impact medium-term intraocular pressure (IOP) reduction compared with placebo, but apraclonidine can be used to blunt immediate postlaser pressure spikes." | 9.34 | Effect of Apraclonidine and Diclofenac on Early Changes in Intraocular Pressure After Selective Laser Trabeculoplasty. ( Bergo, C; Halvorsen, H; Krohn, J; Thrane, AS; Thrane, VR, 2020) |
| "To evaluate the effectiveness of prophylactic topical apraclonidine 1% in preventing an intraocular pressure (IOP) rise in the early period after uneventful phacoemulsification with intraocular lens (IOL) implantation." | 9.10 | Preventing intraocular pressure increase after phacoemulsification and the role of perioperative apraclonidine. ( Desai, SP; Kasetti, SR; Sivakumar, S; Sunderraj, P, 2002) |
| "The authors compared the efficacy of apraclonidine 1% versus pilocarpine 4% prophylaxis of post-argon laser trabeculoplasty (ALT) intraocular pressure (IOP) spike." | 9.09 | Efficacy of apraclonidine 1% versus pilocarpine 4% for prophylaxis of intraocular pressure spike after argon laser trabeculoplasty. ( Birt, CM; Chung, HS; Glover, BK; Hughes, BA; Juzych, MS; Kim, C; Ren, J; Shin, DH, 1999) |
| "2% can control intraocular pressure (IOP) spikes as well as apraclonidine 1." | 9.09 | Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%. ( Barnes, SD; Campagna, JA; Dirks, MS; Doe, EA, 1999) |
| "Topical apraclonidine hydrochloride 1% is effective for controlling the intraocular pressure (IOP) rise following argon laser trabeculoplasty (ALT)." | 9.08 | Apraclonidine 0.5% versus 1% for controlling intraocular pressure elevation after argon laser trabeculoplasty. ( Allingham, RR; Assalian, AA; Shields, MB; Threlkeld, AB, 1996) |
| "0% apraclonidine in preventing laser-induced intraocular pressure (IOP) elevation after trabeculoplasty, neodymium: YAG (Nd: YAG) iridotomy, and capsulotomy." | 9.08 | Apraclonidine and anterior segment laser surgery. Comparison of 0.5% versus 1.0% apraclonidine for prevention of postoperative intraocular pressure rise. ( Gieser, DK; Grewal, RK; Karalekas, DP; Krupin, T; McDaniel, DL; Rosenberg, LF; Ruderman, J; Siegfried, C; Williams, R, 1995) |
| "To measure the effect of 1% apraclonidine hydrochloride eyedrops on intraocular pressure (IOP) after cataract surgery." | 9.08 | The effect of 1% apraclonidine on intraocular pressure after cataract surgery. ( Renzenbrink-Bubberman, AC; Sterk, CC; van Best, JA, 1998) |
| "To investigate if apraclonidine can effectively prevent the acute increase of intraocular pressure (IOP) in brown eyes with Nd:YAG laser iridectomy." | 9.08 | [Apraclonidine prevents the acute increase of intraocular pressure in brown eyes with Nd:YAG laser iridectomy]. ( Liu, X; Mao, J; Zhao, J, 1998) |
| "Apraclonidine effectively decreased large IOP elevations in glaucomatous eyes undergoing trabeculectomy combined with extracapsular cataract surgery." | 9.07 | Effect of topical apraclonidine on the frequency of intraocular pressure elevations after combined extracapsular cataract extraction and trabeculectomy. ( Robin, AL, 1993) |
| "To evaluate the effect of topical apraclonidine on early postoperative intraocular pressure and blood-aqueous barrier permeability, we conducted a double-masked clinical trial in which 37 patients undergoing uncomplicated phacoemulsification and posterior chamber intraocular lens implantation were randomly assigned to treatment with 1% apraclonidine or its vehicle." | 9.07 | Effects of apraclonidine on intraocular pressure and blood-aqueous barrier permeability after phacoemulsification and intraocular lens implantation. ( Araie, M; Ishi, K, 1993) |
| "We conducted a randomly assigned, double-masked, controlled clinical trial to assess the efficacy of 1% apraclonidine hydrochloride in controlling postoperative intraocular pressure increases in patients undergoing extracapsular cataract extraction." | 9.07 | Control of intraocular pressure with apraclonidine hydrochloride after cataract extraction. ( Ide, CH; MacKenzie, D; Wiles, SB, 1991) |
| "A randomized, prospective, double-masked study was undertaken to determine the risk of postcycloplegic intraocular pressure spikes in patients with open-angle glaucoma and to evaluate apraclonidine prophylaxis in minimizing these spikes." | 9.07 | Apraclonidine prophylaxis for postcycloplegic intraocular pressure spikes. ( Baerveldt, G; Heuer, DK; Hill, RA; Lee, M; Martone, JF; Minckler, DS, 1991) |
| "We performed a prospective study that evaluated whether pretreatment with topical flurbiprofen alters the intraocular pressure (IOP) lowering effects of either topical 1% apraclonidine hydrochloride or 0." | 9.07 | Effects of topical flurbiprofen on the intraocular pressure lowering effects of apraclonidine and timolol. ( Arkin, LM; Cummings, HL; Robin, AL; Sulewski, ME, 1991) |
| "We evaluated the prophylactic effect of 1% apraclonidine HCl in controlling the increase in intraocular pressure after Nd:YAG posterior capsulotomy in a large, multicenter double-masked clinical trial." | 9.07 | Prophylactic use of apraclonidine for intraocular pressure increase after Nd:YAG capsulotomies. ( Brint, SF; Burk, LL; deFaller, JM; McCarty, GR; Olander, KW; Silverstone, DE; Taylor, RB, 1992) |
| "A prospective, randomized, double-masked pilot study compared topical 1% ALO 2145 (p-aminoclonidine hydrochloride, a topical alpha 2-agonist) with a placebo to determine its ability to minimize any acute postoperative intraocular pressure (IOP) increase after argon laser iridotomy." | 9.06 | Effects of topical ALO 2145 (p-aminoclonidine hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy. ( deFaller, JM; Pollack, IP; Robin, AL, 1987) |
| "0% apraclonidine hydrochloride in 15 normal volunteers and 17 subjects with increased intraocular pressure." | 9.06 | A limited comparison of apraclonidine's dose response in subjects with normal or increased intraocular pressure. ( Abrams, DA; Caldwell, DR; Crandall, AS; Pollack, IP; Rader, JE; Reaves, TA; Robin, AL; Schnitzer, DB, 1989) |
| "We studied apraclonidine hydrochloride (aplonidine hydrochloride or ALO 2145), an alpha-agonist, for its effect on the intraocular pressure (IOP) rise following neodymium-YAG posterior capsulotomy (YPC)." | 9.06 | Prevention of the rise in intraocular pressure following neodymium-YAG posterior capsulotomy using topical 1% apraclonidine. ( Brown, RH; Crandall, AS; Pollack, IP; Robin, AL; Stewart, RH; White, GL, 1988) |
| "The authors compared the additive intraocular pressure (IOP)-lowering effects of two different topical medications, apraclonidine hydrochloride and dipivefrin hydrochloride, when used in conjunction with timolol maleate." | 9.06 | Adjunctive glaucoma therapy. A comparison of apraclonidine to dipivefrin when added to timolol maleate. ( Morrison, JC; Robin, AL, 1989) |
| "To investigate the effects of apraclonidine on intraocular pressure elevation after cataract surgery and the factors associated with elevated intraocular pressure." | 7.80 | [Factors influencing intraocular pressure elevation on the first postoperative day following small-incision cataract surgery--the effect of apraclonidine]. ( Ando, H; Ando, N; Eguchi, R; Ishikawa, N; Takagi, C, 2014) |
| "To determine the incidence of intraocular pressure (IOP) rise of varying degrees after laser peripheral iridotomy (LPI) in patients with and without glaucoma treated perioperatively with pilocarpine and apraclonidine." | 7.70 | The rarity of clinically significant rise in intraocular pressure after laser peripheral iridotomy with apraclonidine. ( Gangnon, R; Heatley, GA; Kaufman, PL; Lewis, R; Perkins, TW, 1998) |
| "This pilot study evaluated the acute effects of topical ocular apraclonidine 1% (Iopidine) in 10 patients with presumed silicone oil-induced secondary glaucoma (SOIG) and in 10 patients with high-pressure primary open-angle glaucoma (POAG) despite maximum tolerated medical therapy." | 7.69 | Efficacy of apraclonidine ophthalmic solution (Iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma. ( Busche, S; Gramer, E; Kampik, A; Parsons, D, 1995) |
| "0% apraclonidine in preventing intraocular pressure (IOP) spike after argon laser trabeculoplasty (ALT) in patients on chronic apraclonidine therapy compared with patients not on chronic apraclonidine use." | 7.69 | Chronic use of apraclonidine decreases its moderation of post-laser intraocular pressure spikes. ( Birt, CM; Chung, HS; Hakimzadeh, R; Juzych, MS; Kim, C; Lee, D; Levin, DS; Shin, DH, 1997) |
| "The effects of the selective alpha2-adrenergic agonist p-aminoclonidine, the nonselective adrenergic agonist epinephrine, the selective beta2-adrenergic agonist fenoterol and the adenosine A1 agonist R-PIA on intraocular pressure were studied in control and pertussis toxin-pretreated rabbits." | 7.69 | Effects of drugs acting on adrenergic and adenosine receptors on the intraocular pressure and the activity of adenylyl cyclase in ciliary processes and their sensitivity to pertussis toxin. ( Caicedo, M; Cepelík, J; Dedina, M; Hynie, S, 1997) |
| "5% apraclonidine may be a useful adjunct to other antiglaucoma treatment modalities in dogs, but is unlikely to be effective as the sole agent in most forms of canine glaucoma." | 7.69 | Effects of topical administration of 0.5% apraclonidine on intraocular pressure, pupil size, and heart rate in clinically normal dogs. ( Miller, PE; Nelson, MJ; Rhaesa, SL, 1996) |
| "5% apraclonidine, on intraocular pressure (IOP), pupil size, and heart rate in clinically normal cats." | 7.69 | Effects of topical administration of 0.5% apraclonidine on intraocular pressure, pupil size, and heart rate in clinically normal cats. ( Miller, PE; Rhaesa, SL, 1996) |
| "We retrospectively compared the incidence and level of postoperative intraocular pressure (IOP) spikes in 53 consecutive glaucoma patients undergoing Nd:YAG posterior capsulotomy (YPC) who received apraclonidine immediately postoperatively, with those occurring in 22 consecutive similar patients who did not receive apraclonidine." | 7.68 | The effect of apraclonidine on the intraocular pressure of glaucoma patients following Nd:YAG laser posterior capsulotomy. ( Cullom, RD; Schwartz, LW, 1993) |
| "We evaluated the effectiveness of topical apraclonidine (ALO 2145, p-amino clonidine hydrochloride) in suppressing an acute postoperative intraocular pressure (IOP) rise following Nd:YAG laser iridotomy." | 7.67 | Use of apraclonidine to reduce acute intraocular pressure rise following Q-switched Nd:YAG laser iridotomy. ( Kitazawa, Y; Sugiyama, K; Taniguchi, T, 1989) |
| "Intraocular pressure was measured by a masked observer, using Goldmann applanation tonometry, before and 1 hour after the treatment." | 6.69 | Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures. ( Assalian, A; Chevrier, RL; Duperré, J; Lesk, MR, 1999) |
| "Apraclonidine 1." | 6.69 | Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma. ( Chang, FW; Kolin, T; Nishimoto, JH; Tang, IH, 1999) |
| "In apraclonidine-treated eyes the IOP fell from a mean of 15." | 6.66 | Effectiveness of apraclonidine in preventing the rise in intraocular pressure after neodymium:YAG posterior capsulotomy. ( Brown, RH; Crandall, AS; Pollack, IP; Robin, AL; Stewart, RH; White, GL, 1988) |
| "5% apraclonidine on Intraocular pressure (IOP) in horses and compare the effects of timolol maleate 0." | 5.51 | Effect of Topically Applied 0.5% Apraclonidine Versus 0.5% Timolol Maleate on Intraocular Pressure of Healthy Horses. ( Asghari, A; Ozmaie, S; Rajaei, SM; Ziadi, A, 2022) |
| "PRéCIS:: Adjuvant diclofenac and apraclonidine eye drop given in conjunction with selective laser trabeculoplasty (SLT) do not significantly impact medium-term intraocular pressure (IOP) reduction compared with placebo, but apraclonidine can be used to blunt immediate postlaser pressure spikes." | 5.34 | Effect of Apraclonidine and Diclofenac on Early Changes in Intraocular Pressure After Selective Laser Trabeculoplasty. ( Bergo, C; Halvorsen, H; Krohn, J; Thrane, AS; Thrane, VR, 2020) |
| "05 mL of bevacizumab or ranibizumab), that were divided into five groups, group 1: no intraocular pressure (IOP)-lowering medication (n=50); group 2: apraclonidine 1 % one drop 2 hours prior to IVI (n=50); group 3: acetazolamide 250 mg 2 hours prior (n=50); group 4: fixed combination brimonidine+timolol (n=30); group 5: fixed combination dorzolamide+timolol (n=30)." | 5.16 | [Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections]. ( Dot, C; El Chehab, H; Giraud, JM; Le Corre, A; Ract-Madoux, G; Swalduz, B, 2012) |
| "To determine the 1- and 3-hour changes in intraocular pressure after neodymium:yttrium-aluminum-garnet (Nd:YAG) capsulotomy in pseudophakic patients with glaucoma and to determine the effect of acetazolamide and apraclonidine on these changes." | 5.11 | Neodymium:yttrium-aluminum-garnet capsulotomy and intraocular pressure in pseudophakic patients with glaucoma. ( Barnes, EA; Behrend, M; Cahill, A; Kehoe, B; Murdoch, IE; Subramaniam, S, 2004) |
| "To evaluate the effectiveness of prophylactic topical apraclonidine 1% in preventing an intraocular pressure (IOP) rise in the early period after uneventful phacoemulsification with intraocular lens (IOL) implantation." | 5.10 | Preventing intraocular pressure increase after phacoemulsification and the role of perioperative apraclonidine. ( Desai, SP; Kasetti, SR; Sivakumar, S; Sunderraj, P, 2002) |
| "Topical timolol and apraclonidine significantly reduced the intraocular pressure." | 5.09 | A comparative study on the effects of apraclonidine and timolol on the ophthalmic blood flow velocity waveforms. ( Oruç, S; Sener, EC, 1999) |
| " Following the addition of apraclonidine the mean, peak and range of IOP were statistically similar between groups and only the standard deviations remained higher in the exfoliation glaucoma group (p < 0." | 5.09 | The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients. ( Konstas, AG; Maltezos, A; Mantziris, DA; Sine, CS; Stewart, WC, 1999) |
| " Both reduce intraocular pressure in the timolol-treated eye, primarily, if not exclusively, by further suppressing aqueous flow." | 5.09 | Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents. ( Brubaker, RF; Maus, TL; Nau, C, 1999) |
| "2% topical medication or the replacement of apraclonidine with brimonidine resulted in a significant decrease in mean intraocular pressure from 20." | 5.09 | Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy. ( Cha, SC; Glover, BK; Kim, C; Kim, YY; Nguyen, KD; Shin, DH, 1999) |
| "The authors compared the efficacy of apraclonidine 1% versus pilocarpine 4% prophylaxis of post-argon laser trabeculoplasty (ALT) intraocular pressure (IOP) spike." | 5.09 | Efficacy of apraclonidine 1% versus pilocarpine 4% for prophylaxis of intraocular pressure spike after argon laser trabeculoplasty. ( Birt, CM; Chung, HS; Glover, BK; Hughes, BA; Juzych, MS; Kim, C; Ren, J; Shin, DH, 1999) |
| "2% can control intraocular pressure (IOP) spikes as well as apraclonidine 1." | 5.09 | Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%. ( Barnes, SD; Campagna, JA; Dirks, MS; Doe, EA, 1999) |
| "To measure the effect of 1% apraclonidine hydrochloride eyedrops on intraocular pressure (IOP) after cataract surgery." | 5.08 | The effect of 1% apraclonidine on intraocular pressure after cataract surgery. ( Renzenbrink-Bubberman, AC; Sterk, CC; van Best, JA, 1998) |
| "The mechanism by which apraclonidine, an alpha 2-adrenergic agonist, lowers intraocular pressure (IOP) was evaluated in humans." | 5.08 | Effects of apraclonidine on aqueous humor dynamics in human eyes. ( Camras, CB; Tafoya, ME; Toris, CB; Yablonski, ME, 1995) |
| "0% apraclonidine in preventing laser-induced intraocular pressure (IOP) elevation after trabeculoplasty, neodymium: YAG (Nd: YAG) iridotomy, and capsulotomy." | 5.08 | Apraclonidine and anterior segment laser surgery. Comparison of 0.5% versus 1.0% apraclonidine for prevention of postoperative intraocular pressure rise. ( Gieser, DK; Grewal, RK; Karalekas, DP; Krupin, T; McDaniel, DL; Rosenberg, LF; Ruderman, J; Siegfried, C; Williams, R, 1995) |
| "We determined whether the addition of topical apraclonidine hydrochloride to eyes that are receiving maximal medical therapy but still have inadequate intraocular pressure control and that are scheduled to undergo surgery could adequately decrease intraocular pressure, postponing the need for further intervention." | 5.08 | Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group. ( Lehmann, RP; Mundorf, T; Ritch, R; Robin, AL; Shin, DH; Smythe, B, 1995) |
| "The intraocular pressure was reduced significantly in apraclonidine treated eyes by 15." | 5.08 | Effects of 0.5% apraclonidine on optic nerve head and peripapillary retinal blood flow. ( Kim, DM; Kim, TW, 1997) |
| "We determined whether the addition of topical apraclonidine hydrochloride to eyes receiving maximal medical therapy, with inadequate intraocular pressure (IOP) control, and scheduled to undergo surgery, could adequately lower IOP, postponing the need for surgical intervention." | 5.08 | Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group. ( Lehmann, RP; Mundorf, T; Ritch, R; Robin, AL; Shin, D; Smythe, B, 1995) |
| "Apraclonidine suppressed aqueous humor flow between 39% and 44% and lowered intraocular pressure between 20% and 23%." | 5.08 | Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans. ( Brubaker, RF; Maus, TL; Nau, CB; Schadlu, R, 1998) |
| "Topical apraclonidine hydrochloride 1% is effective for controlling the intraocular pressure (IOP) rise following argon laser trabeculoplasty (ALT)." | 5.08 | Apraclonidine 0.5% versus 1% for controlling intraocular pressure elevation after argon laser trabeculoplasty. ( Allingham, RR; Assalian, AA; Shields, MB; Threlkeld, AB, 1996) |
| "To investigate if apraclonidine can effectively prevent the acute increase of intraocular pressure (IOP) in brown eyes with Nd:YAG laser iridectomy." | 5.08 | [Apraclonidine prevents the acute increase of intraocular pressure in brown eyes with Nd:YAG laser iridectomy]. ( Liu, X; Mao, J; Zhao, J, 1998) |
| "The short-term additive effect and side effects of adding 1% apraclonidine hydrochloride to nonselective beta-blockers were investigated in 21 patients with ocular hypertension or early primary open-angle glaucoma." | 5.07 | Additive effect of 1% apraclonidine hydrochloride to nonselective beta-blockers. ( Lee, SH; Lee, SY; Parrow, KA; Shin, DH; Yaldo, MK, 1991) |
| "A randomized, prospective, double-masked study was undertaken to determine the risk of postcycloplegic intraocular pressure spikes in patients with open-angle glaucoma and to evaluate apraclonidine prophylaxis in minimizing these spikes." | 5.07 | Apraclonidine prophylaxis for postcycloplegic intraocular pressure spikes. ( Baerveldt, G; Heuer, DK; Hill, RA; Lee, M; Martone, JF; Minckler, DS, 1991) |
| "To determine the effect of apraclonidine hydrochloride on the acute intraocular pressure (IOP) rise after argon laser iridotomy (ALI), a double-masked comparative study was carried out." | 5.07 | Effect of apraclonidine hydrochloride on acute introacular pressure rise after argon laser iridotomy. ( Hong, C; Park, WH; Sohn, YH; Song, KY, 1991) |
| "We conducted a randomly assigned, double-masked, controlled clinical trial to assess the efficacy of 1% apraclonidine hydrochloride in controlling postoperative intraocular pressure increases in patients undergoing extracapsular cataract extraction." | 5.07 | Control of intraocular pressure with apraclonidine hydrochloride after cataract extraction. ( Ide, CH; MacKenzie, D; Wiles, SB, 1991) |
| "We evaluated the prophylactic effect of 1% apraclonidine HCl in controlling the increase in intraocular pressure after Nd:YAG posterior capsulotomy in a large, multicenter double-masked clinical trial." | 5.07 | Prophylactic use of apraclonidine for intraocular pressure increase after Nd:YAG capsulotomies. ( Brint, SF; Burk, LL; deFaller, JM; McCarty, GR; Olander, KW; Silverstone, DE; Taylor, RB, 1992) |
| "Apraclonidine and pilocarpine have been shown to be effective in reducing the incidence of intraocular pressure (IOP) spikes following argon laser trabeculoplasty." | 5.07 | Influence of apraclonidine and pilocarpine alone and in combination on post laser trabeculoplasty pressure rise. ( Cunliffe, IA; Dapling, RB; Longstaff, S, 1994) |
| "Apraclonidine effectively decreased large IOP elevations in glaucomatous eyes undergoing trabeculectomy combined with extracapsular cataract surgery." | 5.07 | Effect of topical apraclonidine on the frequency of intraocular pressure elevations after combined extracapsular cataract extraction and trabeculectomy. ( Robin, AL, 1993) |
| "Apraclonidine effectively lowers IOP associated with open-angle glaucoma or ocular hypertension; these pilot results will need to be confirmed by a larger pivotal study." | 5.07 | Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study. ( Chuniaud, M; Demailly, P; Hitchings, RA; Nagasubramanian, S; Pannarale, MR; Parsons, DG; Pecori-Giraldi, J; Stodtmeister, R, 1993) |
| "To evaluate the effect of topical apraclonidine on early postoperative intraocular pressure and blood-aqueous barrier permeability, we conducted a double-masked clinical trial in which 37 patients undergoing uncomplicated phacoemulsification and posterior chamber intraocular lens implantation were randomly assigned to treatment with 1% apraclonidine or its vehicle." | 5.07 | Effects of apraclonidine on intraocular pressure and blood-aqueous barrier permeability after phacoemulsification and intraocular lens implantation. ( Araie, M; Ishi, K, 1993) |
| "Sixty patients with medically uncontrolled open-angle glaucoma (intraocular pressure greater than 21 mm Hg) were randomly assigned to one of two treatment regimens with apraclonidine before undergoing 360-degree argon laser trabeculoplasty." | 5.07 | Apraclonidine and argon laser trabeculoplasty. ( Brodstein, DE; Chase, RD; Chopra, H; Goldenfeld, M; Holmwood, PC; Krupin, T; Rosenberg, LF; Ruderman, JM; Tallman, BA, 1992) |
| "We performed a prospective, randomized double blind study comparing the cardiovascular and intraocular pressure (IOP) effects of unilateral therapy with clonidine 0." | 5.07 | Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers. ( Caglar, Y; Elibol, O; Güler, C; Yüksel, N, 1992) |
| "0% apraclonidine (para-aminoclonidine) in preventing the rise of intraocular pressure following anterior segment, laser surgery was evaluated in a randomised double-masked study." | 5.06 | Efficacy and safety of apraclonidine in patients undergoing anterior segment laser surgery. ( Badrinath, SS; Sridharrao, B, 1989) |
| "0% apraclonidine hydrochloride in 15 normal volunteers and 17 subjects with increased intraocular pressure." | 5.06 | A limited comparison of apraclonidine's dose response in subjects with normal or increased intraocular pressure. ( Abrams, DA; Caldwell, DR; Crandall, AS; Pollack, IP; Rader, JE; Reaves, TA; Robin, AL; Schnitzer, DB, 1989) |
| "The authors compared the additive intraocular pressure (IOP)-lowering effects of two different topical medications, apraclonidine hydrochloride and dipivefrin hydrochloride, when used in conjunction with timolol maleate." | 5.06 | Adjunctive glaucoma therapy. A comparison of apraclonidine to dipivefrin when added to timolol maleate. ( Morrison, JC; Robin, AL, 1989) |
| "We performed a double-masked, cross-over, dose-response study of apraclonidine hydrochloride (formerly known as ALO 2145) in 20 patients with elevated intraocular pressure (IOP)." | 5.06 | Apraclonidine. A one-week dose-response study. ( Jampel, HD; Pollack, IP; Quigley, HA; Robin, AL, 1988) |
| "The effect of an alpha adrenergic agonist, ALO 2145 (para-amino-clonidine [PAC]), was examined in a double-masked, multicenter study on the postoperative intraocular pressure (IOP) elevation after laser surgery in 165 patients (83 trabeculoplasty, 36 iridotomy, and 46 capsulotomy)." | 5.06 | ALO 2145 reduces the intraocular pressure elevation after anterior segment laser surgery. ( Brown, RH; Crandall, AS; DeFaller, JM; Gaasterland, DE; Higginbotham, EJ; Lynch, MG; Mandell, AI; Schwartz, AL; Stewart, RH; Wilensky, JT, 1988) |
| "A prospective, randomized, double-masked pilot study compared topical 1% ALO 2145 (p-aminoclonidine hydrochloride, a topical alpha 2-agonist) with a placebo to determine its ability to minimize any acute postoperative intraocular pressure (IOP) increase after argon laser iridotomy." | 5.06 | Effects of topical ALO 2145 (p-aminoclonidine hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy. ( deFaller, JM; Pollack, IP; Robin, AL, 1987) |
| "We studied apraclonidine hydrochloride (aplonidine hydrochloride or ALO 2145), an alpha-agonist, for its effect on the intraocular pressure (IOP) rise following neodymium-YAG posterior capsulotomy (YPC)." | 5.06 | Prevention of the rise in intraocular pressure following neodymium-YAG posterior capsulotomy using topical 1% apraclonidine. ( Brown, RH; Crandall, AS; Pollack, IP; Robin, AL; Stewart, RH; White, GL, 1988) |
| "Clonidine hydrochloride, apraclonidine hydrochloride, and brimonidine tartrate constitute the three topical alpha agonists that are used in the treatment of elevated intraocular pressure." | 4.80 | Selectivity of site of action and systemic effects of topical alpha agonists. ( Burnstein, Y; Robin, AL, 1998) |
| "5% para-amino-clonidine (PAC), an adrenergic alpha 2 agonist, on intraocular pressure (IOP), protein and prostaglandin E2 (PGE2) concentration in aqueous humor following the laser application to the iris of albino rabbits." | 3.72 | The effect of alpha2-agonist on IOP rise following Nd-YAG laser iridotomy. ( Kawai, K; Kitazawa, Y; Sugiyama, K, 2004) |
| "We studied the acute effects of the ocular hypotensive drug, apraclonidine (AP), on intraocular pressure (IOP) and aqueous humor dynamics of anesthetized rats during infusion-induced ocular hypertension." | 3.70 | Aqueous humor dynamics in anesthetized rats infused with intracameral apraclonidine. ( Balaban, CD; Searles, RV; Severs, WB; Shikher, V, 1999) |
| "To determine the location of action of apraclonidine, an alpha-adrenergic receptor agonist that reduces aqueous production and lowers intraocular pressure (IOP)." | 3.70 | Ocular effects of apraclonidine in Horner syndrome. ( Abdul-Rahim, AS; Brown, SM; Crosson, CE; Morales, J, 2000) |
| "To determine the incidence of intraocular pressure (IOP) rise of varying degrees after laser peripheral iridotomy (LPI) in patients with and without glaucoma treated perioperatively with pilocarpine and apraclonidine." | 3.70 | The rarity of clinically significant rise in intraocular pressure after laser peripheral iridotomy with apraclonidine. ( Gangnon, R; Heatley, GA; Kaufman, PL; Lewis, R; Perkins, TW, 1998) |
| "Apraclonidine and brimonidine administered topically to one eye of ketamine-anesthetized normal cynomolgus monkeys each produced a dose-related bilateral reduction in intraocular pressure which was not dependent on intact sympathetic innervation." | 3.69 | Apraclonidine and brimonidine effects on anterior ocular and cardiovascular physiology in normal and sympathectomized monkeys. ( Debink, N; Gabelt, BT; Hubbard, WC; Kaufman, PL; Peterson, CM; Robinson, JC; Wadhwa, A, 1994) |
| "5% apraclonidine may be a useful adjunct to other antiglaucoma treatment modalities in dogs, but is unlikely to be effective as the sole agent in most forms of canine glaucoma." | 3.69 | Effects of topical administration of 0.5% apraclonidine on intraocular pressure, pupil size, and heart rate in clinically normal dogs. ( Miller, PE; Nelson, MJ; Rhaesa, SL, 1996) |
| "The effects of the selective alpha2-adrenergic agonist p-aminoclonidine, the nonselective adrenergic agonist epinephrine, the selective beta2-adrenergic agonist fenoterol and the adenosine A1 agonist R-PIA on intraocular pressure were studied in control and pertussis toxin-pretreated rabbits." | 3.69 | Effects of drugs acting on adrenergic and adenosine receptors on the intraocular pressure and the activity of adenylyl cyclase in ciliary processes and their sensitivity to pertussis toxin. ( Caicedo, M; Cepelík, J; Dedina, M; Hynie, S, 1997) |
| "This pilot study evaluated the acute effects of topical ocular apraclonidine 1% (Iopidine) in 10 patients with presumed silicone oil-induced secondary glaucoma (SOIG) and in 10 patients with high-pressure primary open-angle glaucoma (POAG) despite maximum tolerated medical therapy." | 3.69 | Efficacy of apraclonidine ophthalmic solution (Iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma. ( Busche, S; Gramer, E; Kampik, A; Parsons, D, 1995) |
| "We undertook a retrospective analysis of 64 patients receiving long-term 1% apraclonidine therapy at the University of California-San Francisco Glaucoma Service." | 3.69 | Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. ( Alvarado, J; Butler, P; Hwang, I; Lin, S; Mannschreck, M, 1995) |
| "0% apraclonidine in preventing intraocular pressure (IOP) spike after argon laser trabeculoplasty (ALT) in patients on chronic apraclonidine therapy compared with patients not on chronic apraclonidine use." | 3.69 | Chronic use of apraclonidine decreases its moderation of post-laser intraocular pressure spikes. ( Birt, CM; Chung, HS; Hakimzadeh, R; Juzych, MS; Kim, C; Lee, D; Levin, DS; Shin, DH, 1997) |
| "We retrospectively compared the incidence and level of postoperative intraocular pressure (IOP) spikes in 53 consecutive glaucoma patients undergoing Nd:YAG posterior capsulotomy (YPC) who received apraclonidine immediately postoperatively, with those occurring in 22 consecutive similar patients who did not receive apraclonidine." | 3.68 | The effect of apraclonidine on the intraocular pressure of glaucoma patients following Nd:YAG laser posterior capsulotomy. ( Cullom, RD; Schwartz, LW, 1993) |
| "Apraclonidine (p-aminoclonidine) ophthalmic solution effectively reduces the rise in intraocular pressure (IOP) following anterior segment laser surgery." | 3.68 | Apraclonidine effects on ocular responses to YAG laser irradiation to the rabbit iris. ( Kawai, K; Kitazawa, Y; Sugiyama, K, 1990) |
| "We evaluated the effectiveness of topical apraclonidine (ALO 2145, p-amino clonidine hydrochloride) in suppressing an acute postoperative intraocular pressure (IOP) rise following Nd:YAG laser iridotomy." | 3.67 | Use of apraclonidine to reduce acute intraocular pressure rise following Q-switched Nd:YAG laser iridotomy. ( Kitazawa, Y; Sugiyama, K; Taniguchi, T, 1989) |
| "The intraocular pressures were measured at regular intervals during the 6-months follow-up period." | 2.80 | Influence on intraocular pressure of anti-inflammatory treatments after selective laser trabeculoplasty. ( Anctil, JL; Champagne, S; Des Marchais, B; Goyette, A; Lajoie, C, 2015) |
| "Intraocular pressure was measured preoperatively and 4 to 6 and 24 hours postoperatively." | 2.69 | Medical control of intraocular pressure after cataract surgery. ( Byrd, S; Singh, K, 1998) |
| "Apraclonidine 1." | 2.69 | Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma. ( Chang, FW; Kolin, T; Nishimoto, JH; Tang, IH, 1999) |
| "Intraocular pressure was measured by a masked observer, using Goldmann applanation tonometry, before and 1 hour after the treatment." | 2.69 | Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures. ( Assalian, A; Chevrier, RL; Duperré, J; Lesk, MR, 1999) |
| "5% timolol maleate twice daily for at least 4 weeks and who had 8 AM IOPs of at least 22 mm Hg and no greater than 30 mm Hg 12 hours after dosing were eligible for the study." | 2.68 | The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group. ( Lehmann, RP; Ritch, R; Shin, DH; Shrader, CE; Stewart, WC; van Buskirk, EM, 1995) |
| "5% timolol 8 hours after dosing on days 1, 30, and 90; and a significant difference (P < ." | 2.68 | A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group. ( Horwitz, B; Kottler, M; Laibovitz, R; Ritch, R; Stewart, RH; Stewart, WC, 1996) |
| "When apraclonidine and timolol were given together in the daytime, no clinically significant or statistically significant additive effect was observed." | 2.67 | Apraclonidine and timolol. Combined effects in previously untreated normal subjects. ( Brubaker, RF; Koskela, T, 1991) |
| "In apraclonidine-treated eyes the IOP fell from a mean of 15." | 2.66 | Effectiveness of apraclonidine in preventing the rise in intraocular pressure after neodymium:YAG posterior capsulotomy. ( Brown, RH; Crandall, AS; Pollack, IP; Robin, AL; Stewart, RH; White, GL, 1988) |
| "Apraclonidine was found to significantly decrease conjunctival oxygen tension 76% at 1 hour compared with baseline values." | 2.66 | The effects of apraclonidine on conjunctival oxygen tension. ( Galustian, J; Lewis, RA; Serdahl, CL, 1989) |
| "Apraclonidine is a alpha 2 adrenergic agonic which is a para-amino derivative of clonidine." | 2.39 | [Effect and side effects of apraclonidine]. ( Stewart, WC, 1996) |
| "The aim of all treatment for glaucoma is to lower intra-ocular pressure." | 2.38 | [Pharmacology aspects of glaucoma]. ( Alm, A; Berggren, L, 1992) |
| "We document the recurrence of a CSMD in a patient subsequent to the instillation of topical ocular hypotensive medications and its resolution on discontinuation of therapy." | 1.35 | Recurrent serous macular detachment after topical ocular hypotensive medication. ( Besada, E; Frauens, BJ; Shechtman, D, 2008) |
| "Clonidine did not cause allergic reaction in patients with proven allergy to apraclonidine, indicating that there is no cross-reactivity with apraclonidine." | 1.31 | Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine. ( Geyer, O; Lazar, M; Neudorfer, M; Pianka, P; Schmidt, KG, 2000) |
| "To evaluate the effect of the chronic use of apraclonidine 0." | 1.29 | Long term effect of apraclonidine. ( Araujo, SV; Bond, JB; Moster, MR; Schmidt, CM; Spaeth, GL; Wilson, RP, 1995) |
| "Apraclonidine-treated eyes showed mydriasis and blanching of the conjunctiva." | 1.29 | Apraclonidine protection of the blood-aqueous barrier from traumatic break-down. ( Bellucci, R; Bonomi, L; Pagliarusco, A; Stefani, L, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (13.57) | 18.7374 |
| 1990's | 91 (65.00) | 18.2507 |
| 2000's | 21 (15.00) | 29.6817 |
| 2010's | 7 (5.00) | 24.3611 |
| 2020's | 2 (1.43) | 2.80 |
| Authors | Studies |
|---|---|
| Munk, SA | 1 |
| Harcourt, D | 1 |
| Ambrus, G | 1 |
| Denys, L | 1 |
| Gluchowski, C | 1 |
| Burke, JA | 1 |
| Kharlamb, AB | 1 |
| Manlapaz, CA | 1 |
| Padillo, EU | 1 |
| Runde, E | 1 |
| Williams, L | 1 |
| Wheeler, LA | 1 |
| Garst, ME | 1 |
| Ziadi, A | 1 |
| Ozmaie, S | 1 |
| Asghari, A | 1 |
| Rajaei, SM | 1 |
| Thrane, VR | 1 |
| Thrane, AS | 1 |
| Bergo, C | 1 |
| Halvorsen, H | 1 |
| Krohn, J | 1 |
| Eguchi, R | 1 |
| Takagi, C | 1 |
| Ishikawa, N | 1 |
| Ando, H | 1 |
| Ando, N | 1 |
| Celik, E | 1 |
| Turkoglu, EB | 1 |
| Altun, G | 1 |
| Alagoz, G | 1 |
| Champagne, S | 1 |
| Anctil, JL | 1 |
| Goyette, A | 1 |
| Lajoie, C | 1 |
| Des Marchais, B | 1 |
| Nakamura-Shibasaki, M | 1 |
| Latief, MA | 1 |
| Ko, JA | 1 |
| Funaishi, K | 1 |
| Kiuchi, Y | 1 |
| Oatts, JT | 1 |
| Wang, X | 1 |
| Loewen, NA | 1 |
| Zhang, L | 1 |
| Weizer, JS | 1 |
| Musch, DC | 1 |
| Besada, E | 1 |
| Shechtman, D | 1 |
| Frauens, BJ | 1 |
| El Chehab, H | 1 |
| Le Corre, A | 1 |
| Giraud, JM | 1 |
| Ract-Madoux, G | 1 |
| Swalduz, B | 1 |
| Dot, C | 1 |
| Sebastiani, A | 2 |
| Parmeggiani, F | 1 |
| Costagliola, C | 1 |
| Ciancaglini, M | 1 |
| D'Oronzo, E | 1 |
| Mastropasqua, L | 1 |
| Kasetti, SR | 1 |
| Desai, SP | 1 |
| Sivakumar, S | 1 |
| Sunderraj, P | 1 |
| Arieta, C | 1 |
| Amaral, M | 1 |
| Matuda, E | 1 |
| Crosta, C | 1 |
| de Carvalho Moreira Filho, D | 1 |
| José, N | 1 |
| Lin, JC | 1 |
| Samuel, F | 1 |
| Katz, LJ | 2 |
| Spaeth, GL | 3 |
| Hoop, J | 1 |
| Cantor, LB | 1 |
| Barnes, EA | 1 |
| Murdoch, IE | 1 |
| Subramaniam, S | 1 |
| Cahill, A | 1 |
| Kehoe, B | 1 |
| Behrend, M | 1 |
| Kawai, K | 2 |
| Sugiyama, K | 3 |
| Kitazawa, Y | 3 |
| Chen, TC | 2 |
| Unal, M | 1 |
| Yücel, I | 1 |
| Akar, Y | 1 |
| Scuderi, G | 1 |
| Regine, F | 1 |
| Perdicchi, A | 1 |
| Mannino, G | 1 |
| Recupero, SM | 1 |
| Kotecha, A | 1 |
| Elsheikh, A | 1 |
| Roberts, CR | 1 |
| Zhu, H | 1 |
| Garway-Heath, DF | 1 |
| Meredith, SP | 1 |
| Swift, L | 1 |
| Eke, T | 1 |
| Broadway, DC | 1 |
| Feibel, RM | 1 |
| Bömer, TG | 2 |
| Lagrèze, WD | 2 |
| Funk, J | 2 |
| Robin, AL | 20 |
| Ritch, R | 4 |
| Shin, DH | 6 |
| Smythe, B | 2 |
| Mundorf, T | 2 |
| Lehmann, RP | 3 |
| Gabelt, BT | 1 |
| Robinson, JC | 1 |
| Hubbard, WC | 1 |
| Peterson, CM | 1 |
| Debink, N | 1 |
| Wadhwa, A | 1 |
| Kaufman, PL | 2 |
| Gramer, E | 1 |
| Busche, S | 1 |
| Kampik, A | 1 |
| Parsons, D | 1 |
| Feist, RM | 1 |
| Palmer, DJ | 1 |
| Fiscella, R | 1 |
| Ernest, JT | 1 |
| Tripathi, R | 1 |
| Torczynski, E | 1 |
| Farber, M | 1 |
| Stewart, WC | 5 |
| Shrader, CE | 1 |
| van Buskirk, EM | 2 |
| Butler, P | 1 |
| Mannschreck, M | 1 |
| Lin, S | 1 |
| Hwang, I | 1 |
| Alvarado, J | 1 |
| Toris, CB | 1 |
| Tafoya, ME | 1 |
| Camras, CB | 3 |
| Yablonski, ME | 1 |
| Hong, C | 2 |
| Song, KY | 2 |
| Cullom, RD | 1 |
| Schwartz, LW | 1 |
| Dapling, RB | 1 |
| Cunliffe, IA | 1 |
| Longstaff, S | 1 |
| Muthusamy, P | 1 |
| Araie, M | 1 |
| Ishi, K | 1 |
| Pfeiffer, N | 2 |
| Nagasubramanian, S | 1 |
| Hitchings, RA | 1 |
| Demailly, P | 1 |
| Chuniaud, M | 1 |
| Pannarale, MR | 1 |
| Pecori-Giraldi, J | 1 |
| Stodtmeister, R | 1 |
| Parsons, DG | 1 |
| Bonomi, L | 1 |
| Bellucci, R | 1 |
| Pagliarusco, A | 1 |
| Stefani, L | 1 |
| Araujo, SV | 2 |
| Bond, JB | 1 |
| Wilson, RP | 1 |
| Moster, MR | 1 |
| Schmidt, CM | 1 |
| Lin, SL | 1 |
| Liang, SS | 1 |
| Laibovitz, R | 1 |
| Horwitz, B | 1 |
| Stewart, RH | 4 |
| Kottler, M | 1 |
| Shin, D | 1 |
| Miller, PE | 2 |
| Nelson, MJ | 1 |
| Rhaesa, SL | 2 |
| Celiker, UO | 1 |
| Celebi, S | 1 |
| Celiker, H | 1 |
| Celebi, H | 1 |
| Azuara-Blanco, A | 1 |
| Lu, DW | 1 |
| Lesk, MR | 2 |
| Threlkeld, AB | 1 |
| Assalian, AA | 1 |
| Allingham, RR | 1 |
| Shields, MB | 3 |
| Drake, MV | 1 |
| Rosenberg, LF | 2 |
| Krupin, T | 2 |
| Ruderman, J | 1 |
| McDaniel, DL | 1 |
| Siegfried, C | 1 |
| Karalekas, DP | 1 |
| Grewal, RK | 1 |
| Gieser, DK | 1 |
| Williams, R | 1 |
| Gross, RL | 1 |
| Pinyero, A | 1 |
| Orengo-Nania, S | 1 |
| Chung, HS | 2 |
| Birt, CM | 2 |
| Kim, C | 3 |
| Lee, D | 1 |
| Levin, DS | 1 |
| Hakimzadeh, R | 1 |
| Juzych, MS | 2 |
| Yüksel, N | 2 |
| Elibol, O | 2 |
| Caglar, Y | 2 |
| Alçelik, T | 1 |
| Garrison, PM | 1 |
| Kim, TW | 1 |
| Kim, DM | 1 |
| Morrison, JC | 3 |
| Nylander, KB | 1 |
| Lauer, AK | 1 |
| Cepurna, WO | 1 |
| Johnson, E | 1 |
| Lamberti, G | 1 |
| Pignalosa, B | 1 |
| Fusco, R | 1 |
| Pignalosa, G | 1 |
| Di Govanni, A | 1 |
| Lee, MS | 1 |
| Pasha, M | 1 |
| Weitzman, M | 1 |
| Sterk, CC | 1 |
| Renzenbrink-Bubberman, AC | 1 |
| van Best, JA | 1 |
| Burnstein, Y | 2 |
| Shelton, K | 1 |
| Higginbotham, EJ | 2 |
| Cepelík, J | 1 |
| Caicedo, M | 1 |
| Dedina, M | 1 |
| Hynie, S | 1 |
| Dinslage, S | 1 |
| McLaren, J | 1 |
| Brubaker, R | 1 |
| Byrd, S | 1 |
| Singh, K | 1 |
| Schadlu, R | 1 |
| Maus, TL | 2 |
| Nau, CB | 1 |
| Brubaker, RF | 5 |
| Lewis, R | 1 |
| Perkins, TW | 1 |
| Gangnon, R | 1 |
| Heatley, GA | 1 |
| Lo Presti, L | 1 |
| Morgese, A | 1 |
| Ravot, M | 1 |
| Brogliatti, B | 1 |
| Boles Carenini, B | 1 |
| Searles, RV | 1 |
| Shikher, V | 1 |
| Balaban, CD | 1 |
| Severs, WB | 1 |
| Gebhardt, DO | 1 |
| Chevrier, RL | 1 |
| Assalian, A | 1 |
| Duperré, J | 1 |
| Nau, C | 1 |
| Kaufman, PF | 1 |
| Glover, BK | 2 |
| Cha, SC | 1 |
| Kim, YY | 1 |
| Nguyen, KD | 1 |
| Ren, J | 1 |
| Hughes, BA | 1 |
| Nishimoto, JH | 1 |
| Chang, FW | 1 |
| Tang, IH | 1 |
| Kolin, T | 1 |
| Barnes, SD | 1 |
| Campagna, JA | 1 |
| Dirks, MS | 1 |
| Doe, EA | 1 |
| Zeki, SM | 1 |
| Konstas, AG | 1 |
| Maltezos, A | 1 |
| Mantziris, DA | 1 |
| Sine, CS | 1 |
| Apătăchioae, I | 1 |
| Chiseliţă, D | 1 |
| Chakraborty, P | 1 |
| Villada, JR | 1 |
| Tinu, A | 1 |
| Sharma, S | 1 |
| Cheung, J | 1 |
| Mittra, RA | 1 |
| Pollack, JS | 1 |
| Dev, S | 1 |
| Han, DP | 1 |
| Mieler, WF | 1 |
| Pulido, JS | 2 |
| Connor, TB | 1 |
| Geyer, O | 1 |
| Schmidt, KG | 1 |
| Pianka, P | 1 |
| Neudorfer, M | 1 |
| Lazar, M | 1 |
| Morales, J | 1 |
| Brown, SM | 1 |
| Abdul-Rahim, AS | 1 |
| Crosson, CE | 1 |
| Oruç, S | 1 |
| Sener, EC | 1 |
| Lai, JS | 1 |
| Tham, CC | 1 |
| Chua, JK | 1 |
| Lam, DS | 1 |
| Kuba, GB | 1 |
| Austermann, P | 1 |
| Ang, RT | 1 |
| Grosskreutz, CL | 1 |
| Pasquale, LR | 1 |
| Fan, JT | 1 |
| Zhao, J | 1 |
| Mao, J | 1 |
| Liu, X | 1 |
| Stîngu, C | 1 |
| Cristescu, A | 1 |
| Dărăban, C | 1 |
| Ioniţă, M | 1 |
| Serghiescu, S | 1 |
| Vocci, MJ | 1 |
| Wahl, JC | 1 |
| Mayer, P | 1 |
| Graves, A | 1 |
| York, B | 1 |
| Enger, C | 2 |
| Sutton, J | 1 |
| Silverstone, DE | 1 |
| Brint, SF | 1 |
| Olander, KW | 1 |
| Taylor, RB | 1 |
| McCarty, GR | 1 |
| deFaller, JM | 4 |
| Burk, LL | 1 |
| Holmwood, PC | 1 |
| Chase, RD | 1 |
| Ruderman, JM | 1 |
| Tallman, BA | 1 |
| Brodstein, DE | 1 |
| Chopra, H | 1 |
| Goldenfeld, M | 1 |
| Romanowski, A | 1 |
| Prata Júnior, JA | 1 |
| Rehder, JR | 1 |
| Mello, PA | 1 |
| Güler, C | 1 |
| Ofner, S | 1 |
| Samples, JR | 1 |
| Alm, A | 1 |
| Berggren, L | 1 |
| Siegel, MJ | 1 |
| Lustgarten, JS | 1 |
| Podos, SM | 2 |
| Sulewski, ME | 1 |
| Cummings, HL | 1 |
| Arkin, LM | 1 |
| Koskela, T | 1 |
| Yaldo, MK | 1 |
| Parrow, KA | 1 |
| Lee, SH | 1 |
| Lee, SY | 1 |
| Hill, RA | 1 |
| Minckler, DS | 1 |
| Lee, M | 1 |
| Heuer, DK | 1 |
| Baerveldt, G | 1 |
| Martone, JF | 1 |
| Park, WH | 1 |
| Sohn, YH | 1 |
| Allf, BE | 1 |
| Gharagozloo, NZ | 2 |
| Coleman, AL | 2 |
| Nesher, R | 2 |
| Kolker, AE | 2 |
| Wilkerson, M | 1 |
| Lewis, RA | 2 |
| Wiles, SB | 1 |
| MacKenzie, D | 1 |
| Ide, CH | 1 |
| Fernandez-Bahamonde, JL | 1 |
| Alcaraz-Michelli, V | 1 |
| King, MH | 1 |
| Richards, DW | 1 |
| Pollack, IP | 7 |
| Rudikoff, MT | 1 |
| Mayer, PR | 1 |
| Wang, RF | 1 |
| Lee, KW | 1 |
| Bhuyan, KC | 1 |
| Bhuyan, DK | 1 |
| Mallick, KS | 1 |
| Sneed, SR | 1 |
| Blodi, CF | 1 |
| Taniguchi, T | 1 |
| Jampel, HD | 2 |
| Abrams, DA | 2 |
| Crandall, AS | 4 |
| Caldwell, DR | 1 |
| Schnitzer, DB | 1 |
| Rader, JE | 1 |
| Reaves, TA | 1 |
| Serdahl, CL | 1 |
| Galustian, J | 1 |
| Sridharrao, B | 1 |
| Badrinath, SS | 1 |
| Dandona, L | 1 |
| Quigley, HA | 2 |
| Brown, RH | 3 |
| White, GL | 2 |
| Lynch, MG | 1 |
| Mandell, AI | 1 |
| Wilensky, JT | 1 |
| Schwartz, AL | 1 |
| Gaasterland, DE | 1 |
| Relf, SJ | 1 |
| DeSantis, L | 1 |
| Fourman, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Short-term Intraocular Pressure Control After YAG Iridotomy - Comparison Between Brimonidine 0.1% vs. 0.2%[NCT01417858] | 50 participants (Anticipated) | Interventional | 2010-11-30 | Recruiting | |||
| Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure[NCT00941525] | Phase 4 | 174 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Prospective, Randomized Study Comparing the Effects of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy[NCT01257698] | 21 participants (Actual) | Interventional | 2010-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients will self-monitor gas bubble duration and will receive weekly phone calls by the study coordinator until gas disappearance is confirmed. (NCT01257698)
Timeframe: Up to 4 weeks
| Intervention | days (Mean) |
|---|---|
| Dorzolamide-timolol Topical Drops | 17.1 |
| Standard of Care | 18.1 |
12 reviews available for apraclonidine and Intraocular Pressure
| Article | Year |
|---|---|
Perioperative medications for preventing temporarily increased intraocular pressure after laser trabeculoplasty.
Topics: Adrenergic alpha-2 Receptor Agonists; Antihypertensive Agents; Brimonidine Tartrate; Clonidine; Conj | 2017 |
Questions concerning the role of apraclonidine in the management of glaucoma.
Topics: Adrenergic alpha-Agonists; Clonidine; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular Hyp | 1995 |
[Review of glaucoma research].
Topics: Adrenergic alpha-Agonists; Carbonic Anhydrase Inhibitors; Clonidine; Glaucoma; Humans; Intraocular P | 1993 |
New medical therapies for glaucoma.
Topics: Adrenergic alpha-Agonists; Carbonic Anhydrase Inhibitors; Clonidine; Glaucoma, Open-Angle; Humans; I | 1996 |
[Effect and side effects of apraclonidine].
Topics: Adrenergic alpha-Agonists; Clonidine; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Press | 1996 |
Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events.
Topics: Adrenergic beta-Antagonists; Brimonidine Tartrate; Cardiovascular System; Central Nervous System; Cl | 1998 |
Selectivity of site of action and systemic effects of topical alpha agonists.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Clonidine; Glauco | 1998 |
Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Aqueous Humor; Brimonidine Tartrate; Clonidine; | 1999 |
[Alpha-2 adrenergic agonists in the treatment of glaucoma].
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Brimonidine Tartrate; Clonidine; Gl | 1999 |
[New developments in drug therapy of glaucoma].
Topics: Adrenergic alpha-Agonists; Carbonic Anhydrase Inhibitors; Clonidine; Glaucoma; Humans; Intraocular P | 1992 |
[Pharmacology aspects of glaucoma].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Calcium Channel Blockers; Carbonic Anhydrase | 1992 |
Medical management of acute postoperative intraocular pressure rises associated with anterior segment ophthalmic laser surgery.
Topics: Anterior Eye Segment; Clonidine; Glaucoma; Humans; Intraocular Pressure; Iris; Laser Therapy; Trabec | 1990 |
75 trials available for apraclonidine and Intraocular Pressure
| Article | Year |
|---|---|
Effect of Topically Applied 0.5% Apraclonidine Versus 0.5% Timolol Maleate on Intraocular Pressure of Healthy Horses.
Topics: Adrenergic alpha-Agonists; Animals; Clonidine; Double-Blind Method; Female; Horse Diseases; Horses; | 2022 |
Effect of Apraclonidine and Diclofenac on Early Changes in Intraocular Pressure After Selective Laser Trabeculoplasty.
Topics: Adrenergic alpha-2 Receptor Agonists; Aged; Anti-Inflammatory Agents, Non-Steroidal; Clonidine; Dicl | 2020 |
Short-term effect of topical brinzolamide 1%-timolol 0.5% fixed combination on human central corneal thickness.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Aged; Capsule Opacification; Carb | 2015 |
Influence on intraocular pressure of anti-inflammatory treatments after selective laser trabeculoplasty.
Topics: Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Clonidine; Combined Modalit | 2015 |
Effect of alpha-2-agonist premedication on intraocular pressure after selective laser trabeculoplasty.
Topics: Adrenergic alpha-2 Receptor Agonists; Aged; Brimonidine Tartrate; Clonidine; Female; Glaucoma, Open- | 2015 |
[Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections].
Topics: Acetazolamide; Aged; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Bevacizumab; Brimon | 2012 |
Effects of acute topical administration of clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2% on visual field parameters and ocular perfusion pressure in patients with primary open-angle glaucoma.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Aged; Blood Pressure; Brimonidine Tartrate; Clon | 2002 |
Preventing intraocular pressure increase after phacoemulsification and the role of perioperative apraclonidine.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Clonidine; Double-Blind | 2002 |
Dorzolamide X apraclonidine in the prevention of the intraocular pressure spike after Nd : YAG laser posterior capsulotomy.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Carbonic Anhydrase Inhibitors; Clonidine; | 2002 |
The effect of topical glaucoma medications evaluated by perimetry.
Topics: Administration, Topical; Antihypertensive Agents; Betaxolol; Clonidine; Epinephrine; Glaucoma; Human | 2003 |
Neodymium:yttrium-aluminum-garnet capsulotomy and intraocular pressure in pseudophakic patients with glaucoma.
Topics: Acetazolamide; Administration, Oral; Administration, Topical; Adrenergic alpha-Agonists; Antihyperte | 2004 |
Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
Topics: Adrenergic alpha-Agonists; Aged; Anterior Eye Segment; Antihypertensive Agents; Blood Pressure; Brim | 2005 |
Brinzolamide 1% versus apraclonidine 0.5% to prevent intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Carbonic Anhydrase Inhibitors; Clonidine; | 2006 |
Comparative efficacy of acetazolamide and apraclonidine in the control of intraocular pressure following phacoemulsification.
Topics: Acetazolamide; Administration, Oral; Administration, Topical; Adrenergic alpha-Agonists; Aged; Aged, | 2006 |
Intraocular pressure rise after phacoemulsification with posterior chamber lens implantation: effect of prophylactic medication, wound closure, and surgeon's experience.
Topics: Acetazolamide; Adrenergic alpha-Antagonists; Aged; Clonidine; Female; Humans; Intraocular Pressure; | 1995 |
Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carbonic Anh | 1995 |
Effectiveness of apraclonidine and acetazolamide in preventing postoperative intraocular pressure spikes after extracapsular cataract extraction.
Topics: Acetazolamide; Administration, Oral; Administration, Topical; Adrenergic alpha-Agonists; Aged; Catar | 1995 |
The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group.
Topics: Adrenergic alpha-Agonists; Chemotherapy, Adjuvant; Clonidine; Double-Blind Method; Drug Administrati | 1995 |
Effects of apraclonidine on aqueous humor dynamics in human eyes.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Anterior Eye Segment; Aqueous Humor; Clonidine; Double-Blind | 1995 |
[Increased intraocular pressure after cataract extraction--effect of surgical technique, surgical procedure and preventive drug administration. A prospective, randomized double-blind study].
Topics: Acetazolamide; Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Cataract Extraction; Clinical Com | 1995 |
Influence of apraclonidine and pilocarpine alone and in combination on post laser trabeculoplasty pressure rise.
Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Blood Pressure; Clonidine; Glaucoma, Open-Angle; | 1994 |
Effect of topical apraclonidine on the frequency of intraocular pressure elevations after combined extracapsular cataract extraction and trabeculectomy.
Topics: Adrenergic alpha-Agonists; Aged; Cataract Extraction; Clonidine; Double-Blind Method; Female; Glauco | 1993 |
Effects of apraclonidine on intraocular pressure and blood-aqueous barrier permeability after phacoemulsification and intraocular lens implantation.
Topics: Adrenergic alpha-Agonists; Aged; Aqueous Humor; Blood; Cataract Extraction; Cell Membrane Permeabili | 1993 |
Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Clonidine; Double-Blind Method; Drug Administration | 1993 |
A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Clonidine; Double-B | 1996 |
Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Clonidine; Doubl | 1995 |
Apraclonidine 0.5% versus 1% for controlling intraocular pressure elevation after argon laser trabeculoplasty.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Clonidine; Follow-Up Studies; Glaucoma; Humans; | 1996 |
Apraclonidine and anterior segment laser surgery. Comparison of 0.5% versus 1.0% apraclonidine for prevention of postoperative intraocular pressure rise.
Topics: Adrenergic alpha-Agonists; Aged; Anterior Eye Segment; Clonidine; Double-Blind Method; Glaucoma; Hum | 1995 |
Short-term effect of apraclonidine on intraocular pressure in glaucoma patients receiving timolol and pilocarpine.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Clonidine; Dr | 1997 |
Effects of 0.5% apraclonidine on optic nerve head and peripapillary retinal blood flow.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Double-Blind Method; Female; Hemodynamics; Humans; Intr | 1997 |
Short-term clinical trial evaluating the efficacy of the combination of apraclonidine 0.5% solution and betaxolol 0.25% suspension.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Betaxolol; Chronic | 1997 |
The effect of 1% apraclonidine on intraocular pressure after cataract surgery.
Topics: Administration, Topical; Adolescent; Adrenergic alpha-Agonists; Cataract Extraction; Clonidine; Doub | 1998 |
Medical control of intraocular pressure after cataract surgery.
Topics: Acetazolamide; Administration, Oral; Administration, Topical; Adrenergic alpha-Agonists; Aged; Carbo | 1998 |
Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
Topics: Adrenergic alpha-Agonists; Adult; Aqueous Humor; Brimonidine Tartrate; Clonidine; Female; Fluorophot | 1998 |
Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Anterior Eye Segment; Brimonidine Tartrat | 1999 |
Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Antihypertensive Agents; Aqueous Humor; Brimonid | 1999 |
Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
Topics: Adrenergic alpha-Agonists; Aged; Brimonidine Tartrate; Chronic Disease; Clonidine; Drug Hypersensiti | 1999 |
Efficacy of apraclonidine 1% versus pilocarpine 4% for prophylaxis of intraocular pressure spike after argon laser trabeculoplasty.
Topics: Aged; Clonidine; Female; Glaucoma, Open-Angle; Humans; Incidence; Intraocular Pressure; Laser Therap | 1999 |
Reversal of intraocular pressure increases with 0.5% apraclonidine after dilated fundus examination in patients with chronic open-angle glaucoma.
Topics: Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Chronic Disease; Clonidine; Double-Blind Method; | 1999 |
Control of intraocular pressure elevations after argon laser trabeculoplasty: comparison of brimonidine 0.2% to apraclonidine 1.0%.
Topics: Adrenergic alpha-Agonists; Aged; Brimonidine Tartrate; Clonidine; Double-Blind Method; Female; Glauc | 1999 |
The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Circadian Rhythm; Clonidine; Drug Ther | 1999 |
The use of topical aqueous suppressants in the prevention of postoperative intraocular pressure elevation after pars plana vitrectomy with long-acting gas tamponade.
Topics: Administration, Topical; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Clonidine; Fl | 2000 |
A comparative study on the effects of apraclonidine and timolol on the ophthalmic blood flow velocity waveforms.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Blood Flow Velocity; Blood Pressure; | 1999 |
[Reduction of ocular pulse amplitude by apraclonidine--prospective double-blind, randomized clinical trial with 10 subjects].
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adult; Clonidine; Double-Blind Method; Female; G | 2001 |
Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
Topics: Adrenergic alpha-Agonists; Aged; Anterior Eye Segment; Blood Pressure; Brimonidine Tartrate; Clonidi | 2001 |
[Apraclonidine prevents the acute increase of intraocular pressure in brown eyes with Nd:YAG laser iridectomy].
Topics: Clonidine; Female; Humans; Intraocular Pressure; Iridectomy; Laser Therapy; Male; Ocular Hypertensio | 1998 |
Reformulation and drop size of apraclonidine hydrochloride.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Double-Blind Method; Female; Formularies as Topic; Huma | 1992 |
Prophylactic use of apraclonidine for intraocular pressure increase after Nd:YAG capsulotomies.
Topics: Adrenergic alpha-Agonists; Aged; Cataract Extraction; Clonidine; Double-Blind Method; Female; Humans | 1992 |
Apraclonidine and argon laser trabeculoplasty.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Clonidine; Glaucoma, Open-Angle; Humans; Intraoc | 1992 |
Apraclonidine and early postoperative intraocular hypertension after cataract extraction.
Topics: Adrenergic alpha-Agonists; Cataract Extraction; Clonidine; Female; Humans; Intraocular Pressure; Len | 1992 |
Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers.
Topics: Adrenergic beta-Agonists; Adult; Aged; Clonidine; Double-Blind Method; Female; Humans; Intraocular P | 1992 |
Effect of flurbiprofen on the reduction of intraocular pressure after administration of 1% apraclonidine in patients with glaucoma.
Topics: Clonidine; Flurbiprofen; Glaucoma; Humans; Intraocular Pressure; Osmolar Concentration | 1992 |
Effects of topical flurbiprofen on the intraocular pressure lowering effects of apraclonidine and timolol.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adult; Clonidine; Double-Blind Method; Evaluatio | 1991 |
Apraclonidine and timolol. Combined effects in previously untreated normal subjects.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Aqueous Humor; Circadian Rhythm; Clonidine; Drug | 1991 |
Additive effect of 1% apraclonidine hydrochloride to nonselective beta-blockers.
Topics: Adrenergic alpha-Agonists; Clonidine; Double-Blind Method; Drug Synergism; Female; Glaucoma, Open-An | 1991 |
Apraclonidine prophylaxis for postcycloplegic intraocular pressure spikes.
Topics: Adrenergic alpha-Agonists; Clonidine; Double-Blind Method; Glaucoma, Open-Angle; Humans; Incidence; | 1991 |
Effect of apraclonidine hydrochloride on acute introacular pressure rise after argon laser iridotomy.
Topics: Acute Disease; Adrenergic alpha-Agonists; Adult; Aged; Clonidine; Double-Blind Method; Female; Glauc | 1991 |
Effect of apraclonidine in long-term timolol users.
Topics: Adrenergic alpha-Agonists; Aged; Aqueous Humor; Clonidine; Double-Blind Method; Drug Administration | 1991 |
Apraclonidine hydrochloride: an evaluation of plasma concentrations, and a comparison of its intraocular pressure lowering and cardiovascular effects to timolol maleate.
Topics: Adrenergic alpha-Agonists; Adult; Blood Pressure; Clonidine; Double-Blind Method; Evaluation Studies | 1990 |
Follicular conjunctivitis associated with apraclonidine.
Topics: Adult; Clonidine; Conjunctivitis; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Male; Timolol | 1991 |
Control of intraocular pressure with apraclonidine hydrochloride after cataract extraction.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Cataract Extraction; Clonidine; Double-Blind M | 1991 |
The combined use of apraclonidine and pilocarpine during laser iridotomy in a Hispanic population.
Topics: Aged; Clonidine; Double-Blind Method; Drug Therapy, Combination; Female; Glaucoma, Angle-Closure; Gl | 1990 |
Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine.
Topics: Administration, Topical; Adult; Analysis of Variance; Blood Pressure; Cardiovascular System; Chi-Squ | 1990 |
Adjunctive glaucoma therapy. A comparison of apraclonidine to dipivefrin when added to timolol maleate.
Topics: Adult; Aged; Clinical Trials as Topic; Clonidine; Drug Therapy, Combination; Epinephrine; Eye Diseas | 1989 |
A limited comparison of apraclonidine's dose response in subjects with normal or increased intraocular pressure.
Topics: Adult; Aged; Circadian Rhythm; Clinical Trials as Topic; Clonidine; Dose-Response Relationship, Drug | 1989 |
The effects of apraclonidine on conjunctival oxygen tension.
Topics: Administration, Topical; Adult; Clonidine; Conjunctiva; Female; Humans; Intraocular Pressure; Male; | 1989 |
Efficacy and safety of apraclonidine in patients undergoing anterior segment laser surgery.
Topics: Adult; Aged; Anterior Eye Segment; Blood Pressure; Clonidine; Female; Heart Rate; Humans; Intraocula | 1989 |
"Outlier" intraocular pressure readings: valid or invalid for statistical analysis?
Topics: Analysis of Variance; Clinical Trials as Topic; Clonidine; Data Interpretation, Statistical; Double- | 1989 |
Effectiveness of apraclonidine in preventing the rise in intraocular pressure after neodymium:YAG posterior capsulotomy.
Topics: Administration, Topical; Aged; Clonidine; Female; Glaucoma; Humans; Intraocular Pressure; Laser Ther | 1988 |
Apraclonidine. A one-week dose-response study.
Topics: Administration, Topical; Adult; Aged; Clinical Trials as Topic; Clonidine; Dose-Response Relationshi | 1988 |
ALO 2145 reduces the intraocular pressure elevation after anterior segment laser surgery.
Topics: Aged; Anterior Eye Segment; Clinical Trials as Topic; Clonidine; Double-Blind Method; Female; Humans | 1988 |
Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145).
Topics: Administration, Topical; Adult; Aqueous Humor; Clonidine; Double-Blind Method; Female; Humans; Intra | 1988 |
Effects of topical ALO 2145 (p-aminoclonidine hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy.
Topics: Argon; Clonidine; Humans; Intraocular Pressure; Iris; Laser Therapy; Postoperative Period; Prospecti | 1987 |
Prevention of the rise in intraocular pressure following neodymium-YAG posterior capsulotomy using topical 1% apraclonidine.
Topics: Administration, Topical; Aged; Cataract Extraction; Clonidine; Double-Blind Method; Female; Humans; | 1988 |
Short-term effects of unilateral 1% apraclonidine therapy.
Topics: Administration, Topical; Adult; Circadian Rhythm; Clonidine; Drug Hypersensitivity; Eye; Eyelids; Fe | 1988 |
53 other studies available for apraclonidine and Intraocular Pressure
| Article | Year |
|---|---|
Synthesis and evaluation of 2-[(5-methylbenz-1-ox-4-azin-6-yl)imino]imidazoline, a potent, peripherally acting alpha 2 adrenoceptor agonist.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Imidazoles; Intraocular Pr | 1996 |
[Factors influencing intraocular pressure elevation on the first postoperative day following small-incision cataract surgery--the effect of apraclonidine].
Topics: Adrenergic alpha-2 Receptor Agonists; Aged; Cataract Extraction; Clonidine; Female; Humans; Intraocu | 2014 |
Effects of topical adrenergic agents on prostaglandin E2-induced aqueous flare and intraocular pressure elevation in pigmented rabbits.
Topics: Administration, Topical; Adrenergic Agonists; Animals; Aqueous Humor; Blood-Aqueous Barrier; Brimoni | 2016 |
Recurrent serous macular detachment after topical ocular hypotensive medication.
Topics: Administration, Topical; Antihypertensive Agents; Clonidine; Drug Combinations; Drug Therapy, Combin | 2008 |
The effect of alpha2-agonist on IOP rise following Nd-YAG laser iridotomy.
Topics: Adrenergic alpha-Agonists; Animals; Aqueous Humor; Clonidine; Dinoprostone; Eye Proteins; Intraocula | 2004 |
Corneal thickness- and age-related biomechanical properties of the cornea measured with the ocular response analyzer.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Aging; Biomechanical Phenomena; Clonidine | 2006 |
The acute morphologic changes that occur at the optic nerve head induced by medical reduction of intraocular pressure.
Topics: Acetazolamide; Administration, Oral; Administration, Topical; Adrenergic alpha-Agonists; Aged; Aged, | 2007 |
High incidence of topical allergic reactions to 1% apraclonidine.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Clonidine; Drug Hypersensitivity; Glaucoma; Huma | 1995 |
Apraclonidine and brimonidine effects on anterior ocular and cardiovascular physiology in normal and sympathectomized monkeys.
Topics: Adrenergic alpha-Agonists; Animals; Aqueous Humor; Blood Pressure; Body Weight; Brimonidine Tartrate | 1994 |
Efficacy of apraclonidine ophthalmic solution (Iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Clonidine; Drug Tolerance; Fe | 1995 |
Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions.
Topics: Adrenergic alpha-Agonists; Aged; Clonidine; Drug Hypersensitivity; Female; Follow-Up Studies; Glauco | 1995 |
Effect of apraclonidine hydrochloride on the attack of Posner-Schlossman syndrome.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Clonidine; Female; Glaucoma, Open-Angle; Hemodyn | 1993 |
The effect of apraclonidine on the intraocular pressure of glaucoma patients following Nd:YAG laser posterior capsulotomy.
Topics: Adrenergic alpha-Agonists; Aged; Clonidine; Female; Glaucoma; Humans; Incidence; Intraocular Pressur | 1993 |
Apraclonidine in the management of glaucomatocyclitic crisis.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Female; Glaucoma, Open-Angle; Humans; Intraocular Press | 1994 |
Apraclonidine protection of the blood-aqueous barrier from traumatic break-down.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Aqueous Humor; Blood-Aqueous Barri | 1995 |
Long term effect of apraclonidine.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Clonidine; Female; Follow- | 1995 |
Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution.
Topics: Adrenergic alpha-Agonists; Adult; Blinking; Blood Pressure; Clonidine; Conjunctiva; Cornea; Drug Eva | 1995 |
Effects of topical administration of 0.5% apraclonidine on intraocular pressure, pupil size, and heart rate in clinically normal dogs.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Animals; Cats; Circadian Rhythm; Clonidine; Dog | 1996 |
Effects of topical administration of 0.5% apraclonidine on intraocular pressure, pupil size, and heart rate in clinically normal cats.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Animals; Cats; Clonidine; Dogs; Female; Heart Ra | 1996 |
Effect of topical apraclonidine on flow properties of central retinal and ophthalmic arteries.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adult; Blood Flow Velocity; Clonidine; Female; H | 1996 |
Effects of apraclonidine on short-term outcome of glaucoma surgery.
Topics: Adrenergic alpha-Agonists; Aged; Clonidine; Female; Glaucoma; Humans; Intraocular Pressure; Male; Mi | 1996 |
Clinical experience with apraclonidine 0.5%.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Child; Chronic Disease; Cloni | 1997 |
Chronic use of apraclonidine decreases its moderation of post-laser intraocular pressure spikes.
Topics: Adrenergic alpha-Agonists; Aged; Clonidine; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressu | 1997 |
Glaucoma drops control intraocular pressure and protect optic nerves in a rat model of glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Betaxolol; Clonidine; Disease Model | 1998 |
The effect of aqueous humor suppressants on intravitreal gas bubble duration in rabbits.
Topics: Absorption; Administration, Topical; Animals; Aqueous Humor; Clonidine; Fluorocarbons; Injections; I | 1998 |
Glaucomatocyclitic crisis in a child.
Topics: Adolescent; Clonidine; Corneal Edema; Diagnosis, Differential; Drug Therapy, Combination; Glaucoma; | 1998 |
Effects of drugs acting on adrenergic and adenosine receptors on the intraocular pressure and the activity of adenylyl cyclase in ciliary processes and their sensitivity to pertussis toxin.
Topics: Adenosine; Adenylate Cyclase Toxin; Adenylyl Cyclases; Adrenergic Agonists; Adrenergic alpha-Antagon | 1997 |
Intraocular pressure in rabbits by telemetry II: effects of animal handling and drugs.
Topics: Animal Husbandry; Animals; Circadian Rhythm; Clonidine; Epinephrine; Intraocular Pressure; Latanopro | 1998 |
The rarity of clinically significant rise in intraocular pressure after laser peripheral iridotomy with apraclonidine.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Clonidine; Female | 1998 |
Ultrabiomicroscopic study of the effects of brimonidine, apraclonidine, latanoprost and ibopamine on the chamber angle and ciliary body.
Topics: Adrenergic alpha-Agonists; Aged; Anterior Chamber; Brimonidine Tartrate; Ciliary Body; Clonidine; De | 1998 |
Aqueous humor dynamics in anesthetized rats infused with intracameral apraclonidine.
Topics: Adrenergic alpha-Agonists; Analysis of Variance; Anesthesia; Animals; Anterior Chamber; Aqueous Humo | 1999 |
[Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Clonidine; Drug Appr | 1999 |
Inverted U' strategy for short pulsed laser posterior capsulotomy.
Topics: Acetazolamide; Adrenergic alpha-Agonists; Cataract Extraction; Clonidine; Humans; Intraocular Pressu | 1999 |
Medical control of IOP after cataract surgery.
Topics: Acetazolamide; Adrenergic alpha-Agonists; Carbonic Anhydrase Inhibitors; Clonidine; Drug Therapy, Co | 2000 |
Ophthaproblem. Acute angle-closure glaucoma.
Topics: Acetazolamide; Acute Disease; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Carbonic Anhyd | 2000 |
Clonidine provides an allergy-free alternative in glaucoma patients with proven allergy to apraclonidine.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Clonidine; Conjunctivitis, Al | 2000 |
Ocular effects of apraclonidine in Horner syndrome.
Topics: Adrenergic alpha-Agonists; Aqueous Humor; Ciliary Body; Clonidine; Cohort Studies; Horner Syndrome; | 2000 |
Immediate diode laser peripheral iridoplasty as treatment of acute attack of primary angle closure glaucoma: a preliminary study.
Topics: Acute Disease; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Clon | 2001 |
[Iopidine in the control of intraocular pressure after glaucoma laser treatment].
Topics: Adrenergic alpha-Agonists; Clonidine; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Postope | 2001 |
Prophylactic use of apraclonidine for intraocular pressure increase after Nd:YAG Capsulotomies.
Topics: Adrenergic alpha-Agonists; Cataract Extraction; Clonidine; Humans; Intraocular Pressure; Laser Thera | 1992 |
Apraclonidine and argon laser trabeculoplasty.
Topics: Adrenergic alpha-Agonists; Clonidine; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Pilocar | 1992 |
Early intraocular pressure response to laser trabeculoplasty 180 degrees without apraclonidine versus 360 degrees with apraclonidine.
Topics: Adrenergic alpha-Agonists; Aged; Clonidine; Female; Glaucoma; Humans; Intraocular Pressure; Laser Th | 1991 |
Failure of apraclonidine to prevent delayed IOP elevation after Nd:YAG laser posterior capsulotomy.
Topics: Adrenergic alpha-Agonists; Aged; Clonidine; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Lase | 1990 |
Apraclonidine effects on ocular responses to YAG laser irradiation to the rabbit iris.
Topics: Animals; Aqueous Humor; Clonidine; Dinoprostone; Dose-Response Relationship, Radiation; Eye; Eye Pro | 1990 |
Delayed increased intraocular pressure after Nd:YAG laser posterior capsulotomy in a patient treated with apraclonidine.
Topics: Aged; Clonidine; Humans; Intraocular Pressure; Laser Therapy; Lens Capsule, Crystalline; Lens, Cryst | 1990 |
Near syncope and chest tightness after administration of apraclonidine before argon laser iridotomy.
Topics: Aged; Argon; Chest Pain; Clonidine; Female; Humans; Intraocular Pressure; Iris; Laser Therapy; Posto | 1990 |
The role of prostaglandins in the para-aminoclonidine-induced reduction of intraocular pressure.
Topics: Administration, Topical; Animals; Aqueous Humor; Clonidine; Dinoprost; Dinoprostone; Disease Models, | 1989 |
The role of apraclonidine hydrochloride in laser therapy for glaucoma.
Topics: Acetazolamide; Adult; Aged; Animals; Clonidine; Epinephrine; Female; Glaucoma, Open-Angle; Humans; I | 1989 |
Apraclonidine hydrochloride in vitreoretinal surgery.
Topics: Adult; Clonidine; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Retina; Retinal | 1989 |
Use of apraclonidine to reduce acute intraocular pressure rise following Q-switched Nd:YAG laser iridotomy.
Topics: Aged; Clonidine; Female; Glaucoma; Gonioscopy; Humans; Intraocular Pressure; Iris; Laser Therapy; Ma | 1989 |
Hypotony following instillation of apraclonidine for increased intraocular pressure after trabeculoplasty.
Topics: Aged; Clonidine; Humans; Intraocular Pressure; Male; Ocular Hypertension; Recurrence; Trabeculectomy | 1989 |
The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers.
Topics: Adult; Blood Pressure; Body Water; Clonidine; Female; Humans; Intraocular Pressure; Male; Middle Age | 1987 |
Effects of topical ALO 2145 (p-aminoclonidine hydrochloride, aplonidine hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy.
Topics: Administration, Topical; Clonidine; Humans; Intraocular Pressure; Iris; Laser Therapy | 1988 |